🇺🇸 FDA
Patent

US 9211328

Modulation of NKG2D for prolonging survival of a hematopoietic graft

granted A61KA61K2039/505A61K39/39541

Quick answer

US patent 9211328 (Modulation of NKG2D for prolonging survival of a hematopoietic graft) held by The Regents of the University of California expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Dec 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
17
CPC classes
A61K, A61K2039/505, A61K39/39541, A61P, A61P1/00